Pharming provides update on outstanding shares
(Thomson Reuters ONE) -
Leiden, The Netherlands, August 5, 2010. Biotech company Pharming Group NV
("Pharming") (NYSE Euronext: PHARM) today announced that its current number of
outstanding shares has increased from 309,747,614 at July 12, 2010 to
332,865,044 as per today.
The increase of 23,117,430 shares stems from:
* 12,536,035 shares in relation to anti-dilution protection shares due to
former holders of bonds settled in the fourth quarter of 2009, as announced
in the press release on the financial report for the first half of 2010
dated July 21, 2010. The effect of these shares was fully included in the
results of the second quarter 2010;
* 5,000,000 shares following completion of the DNage spin-off as announced on
July 19, 2010; and
* 5,581,395 shares issued in relation to the exercise of warrants issued upon
entering into ?7.5 million private bonds in January 2010.
About Pharming Group NV
Pharming Group NV is developing innovative products for the treatment of genetic
disorders, ageing diseases, specialty products for surgical indications, and
nutritional products. On June 24, the European Medicines Agency adopted a
positive opinion for Ruconest(TM) (Rhucin) for the treatment of angioedema
attacks. Market Authorization in the European Economic Area is therefore
expected to be granted in September 2010. The product is also under development
for follow-on indications, i.e. antibody-mediated rejection (AMR) and delayed
graft function (DGF) following kidney transplantation. The advanced technologies
of the Company include innovative platforms for the production of protein
therapeutics, technology and processes for the purification and formulation of
these products, as well as technology in the field of DNA repair (via DNage).
Recently the partial spin off of DNage was initiated. Additional information is
available on the Pharming website,http://www.pharming.com.
This press release contains forward looking statements that involve known and
unknown risks, uncertainties and other factors, which may cause the actual
results, performance or achievements of the Company to be materially different
from the results, performance or achievements expressed or implied by these
forward looking statements.
Contact:
Ms. Marjolein van Helmond, T: +31 (0)71 52 47 431 or +31 (0)6 109 299 54
[HUG#1436136]
Press release (PDF):
http://hugin.info/132866/R/1436136/381299.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
All reproduction for further distribution is prohibited.
Source: Pharming Group N.V. via Thomson Reuters ONE
Unternehmensinformation / Kurzprofil:
Datum: 05.08.2010 - 18:00 Uhr
Sprache: Deutsch
News-ID 38788
Anzahl Zeichen: 0
contact information:
Town:
Leiden
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 192 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Pharming provides update on outstanding shares"
steht unter der journalistisch-redaktionellen Verantwortung von
Pharming Group N.V. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
